Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On ...

Drugs for metabolic diseases ... is tipped for sales of $1.6 billion. 4) Eli Lilly and Almirall's Ebglyss (lebrikizumab), an anti-IL-13 antibody for atopic dermatitis that offers less frequent ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Drug major Eli Lilly and Co. (LLY) on Tuesday trimmed its fourth-quarter revenue view below the Street estimates, but raised forecast ...

Clarivate’s Drugs to Watch ... Almirall-partnered Ebglyss to make a significant dent in the crowded atopic dermatitis treatment landscape, generating $6 billion in 2030. Lilly and Novo’s ...

Major contributors to 2025 revenues will be new LLY medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla ... It tracks the ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Sales of Eli Lilly's lead drug, tirzepatide ... Last September, the FDA approved Ebglyss for the treatment of eczema. With less frequent dosing, Ebglyss is expected to compete fiercely with ...